NLRP3 Inflammasome’s Activation in Acute and Chronic Brain Diseases—An Update on Pathogenetic Mechanisms and Therapeutic Perspectives with Respect to Other Inflammasomes
Open Access
- 23 March 2023
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 11 (4) , 999
Abstract
Increasingly prevalent acute and chronic human brain diseases are scourges for the elderly. Besides the lack of therapies, these ailments share a neuroinflammation that is triggered/sustained by different innate immunity-related protein oligomers called inflammasomes. Relevant neuroinflammation players such as microglia/monocytes typically exhibit a strong NLRP3 inflammasome activation. Hence the idea that NLRP3 suppression might solve neurodegenerative ailments. Here we review the recent Literature about this topic. First, we update conditions and mechanisms, including RNAs, extracellular vesicles/exosomes, endogenous compounds, and ethnic/pharmacological agents/extracts regulating NLRP3 function. Second, we pinpoint NLRP3-activating mechanisms and known NLRP3 inhibition effects in acute (ischemia, stroke, hemorrhage), chronic (Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, MS, ALS), and virus-induced (Zika, SARS-CoV-2, and others) human brain diseases. The available data show that (i) disease-specific divergent mechanisms activate the (mainly animal) brains NLRP3; (ii) no evidence proves that NLRP3 inhibition modifies human brain diseases (yet ad hoc trials are ongoing); and (iii) no findings exclude that concurrently activated other-than-NLRP3 inflammasomes might functionally replace the inhibited NLRP3. Finally, we highlight that among the causes of the persistent lack of therapies are the species difference problem in disease models and a preference for symptomatic over etiologic therapeutic approaches. Therefore, we posit that human neural cell-based disease models could drive etiological, pathogenetic, and therapeutic advances, including NLRP3’s and other inflammasomes’ regulation, while minimizing failure risks in candidate drug trials.Keywords
Funding Information
- Italian MUR (Ministry of University & Research)
This publication has 482 references indexed in Scilit:
- Genomic responses in mouse models poorly mimic human inflammatory diseasesProceedings of the National Academy of Sciences of the United States of America, 2013
- Critical role for calcium mobilization in activation of the NLRP3 inflammasomeProceedings of the National Academy of Sciences, 2012
- NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitisProceedings of the National Academy of Sciences, 2012
- Extracellular Ca2+ is a danger signal activating the NLRP3 inflammasome through G protein-coupled calcium sensing receptorsNature Communications, 2012
- Sensing damage by the NLRP3 inflammasomeImmunological Reviews, 2011
- GPRC6A regulates prostate cancer progressionThe Prostate, 2011
- When orthologs diverge between human and mouseBriefings in Bioinformatics, 2011
- GPRC6A Mediates the Non-genomic Effects of SteroidsJournal of Biological Chemistry, 2010
- The NALP3 inflammasome is involved in the innate immune response to amyloid-βNature Immunology, 2008
- Mutant SOD1 in cell types other than motor neurons and oligodendrocytes accelerates onset of disease in ALS miceProceedings of the National Academy of Sciences, 2008